Abstract: Methods are provided for the treatment of a host suffering from head ache pain with topical applications of a local anesthetic. The topical local anesthetic composition comprises an effective amount of a local anesthetic in combination with eucalyptol as a penetration enhancing agent, and optionally an additional penetration enhancing agent. The topical local anesthetic composition is applied to a keratinized skin site proximal to target nerves associated with the headache pain, usually to the supraorbital or occipital regions of the head. Upon application of the topical composition, the local anesthetic rapidly penetrates the skin to block conduction in the target nerves and provide pain relief to the host.

Abstract: An apparatus, product formulation, and method for improved dermal permeation of pharmaceuticals wherein the apparatus includes a thin drug formulation reservoir and a heat-generating chamber separated by a first non-permeable wall, wherein the reservoir and chamber are formed in or supported by a housing. The drug formulation reservoir houses or is capable of housing a predetermined amount of a formulation containing pharmaceutically-active agent(s). The heat-generating/temperature-regulating chamber includes a medium for generating controlled heat, preferably a chemical composition made of carbon, iron, water and/or salt which is activated upon contact with air (oxygen).

Abstract: The present invention relates to an anaesthetic veterinary pharmaceutical composition, comprising a general anaesthetic selected from phencyclidine derivatives such as ketamine or tiletamine, as well as 0.015 to 1.25 molar equivalents of selegiline, combined in a single pharmaceutical composition or presented separately.

Abstract: The present invention relates to stabilized topical pharmaceutical preparations. More specifically the present invention relates to a stabilized topical pharmaceutical preparation, based on the solubilization of a eutectic mixture of local anesthetic agents, in base form, which when combined in the presence of a surfactant and water produce a single phase hydrated polymer to be used in obtaining topical anesthesia and also relates to a stabilized antimicrobial topical pharmaceutical preparation.

Abstract: Stick formulations for topical delivery of water soluble and/or water insoluble agents are disclosed. The stick formulations may contain steroids, antibiotics, antifungals, antihistamines anti inflammatories or local anesthetics. The vehicles comprise a combination of waxes and oils and a surfactant in embodiments involving water soluble agents. Methods for preparing the various stick formulations are also disclosed.

Abstract: the instant invention is a method and composition for the treatment of minor skin irritations based upon the use of a carrier oil with the essential oils of eucalyptus, lavender and ti tree added to the oil with a most unique composition capable of reducing the irritation, promoting healing, resisting insects, and take advantage of the science of aromatherapy.

Abstract: A composition is provided for the treatment of dermal burns and is composed of a homogeneous solution of skin conditioners, anesthetics, water, and alcohol in combination with dimethyl ether. The use of dimethyl ether as the propellant and solvent forms a homogeneous solution of ingredients which otherwise have little solubility in each other. This formulation also cools the skin when applied, significantly improving the healing of the burns. A pressurized aerosol container is also provided having a metered dose valve for accurately dispensing metered doses of the dermal burn composition to optimize treatment and prevent freezing of the skin.

Abstract: The composition of the present invention combines the local anaesthetic lidocaine in free base form and the non-CFC aerosol propellant HFC-134a(1,1,1,2-tetrafluoroethane; CF.sub.3 CH.sub.2 F) or HFC-227 (1,1,1,2,3,3,3-Heptafluoropropane; (CF.sub.3 CHFCF.sub.3), or a combination thereof, thus incorporating previously-unattainable amounts of the lidocaine free base in solution in a non-CFC aerosol propellant. This particular form of relatively-concentrated cosolvent-free anaesthetic permits improved inhalation delivery to the airway and lung, and topical airway local anaesthesia is thus readily provided. A method in accordance with the invention provides for release of the anaesthetic in aerosolized form of selected dosage from a canister containing the pressurized local anaesthetic composition into a patient's respiratory system directly or by way of an airway.

Abstract: Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.

Abstract: The present invention is directed to a method and apparatus for the topical application of opioid analgesic drugs such as morphine. Specifically, the present invention relates to a topical application of the opioid drug and specifically a morphine sulphate in a diluted solution to produce an analgesic effect in a localized area and typically in a localized inflamed area and without a transdermal migration of the opioid drug into the blood stream.

Abstract: A topical anesthetic includes about 1-10% by weight lidocaine hydrochloride, about 0.01-0.10% by weight adrenaline, and about 0.25-4% by weight tetracaine hydrochloride, preferably in an aqueous base with about 2% benzyl alcohol or in a gel including about 3% hydroxyethyl cellulose. The topical anesthetic has been found to be at least as effective as TAC (tetracaine hydrochloride, adrenaline, cocaine), but with fewer harmful side effects and at a greatly reduced cost (about 1/10 of the cost of TAC).

Abstract: The present invention provides a topical anesthetic gel composition, comprising: (a) one or more topical anesthetic agents; (b) an adrenergic sympathomimetic compound; and (c) a pharmaceutical gel component. The present invention also provides a topical anesthetic gel composition, comprising: (a) tetracaine HCl, wherein said tetracaine HCl is contained in said composition in an amount of from about 0.01% to about 1.0% by weight, based upon the total weight of said composition; (b) epinephrine HCl topical solution, wherein said epinephrine HCl is contained in said composition in an amount of from about 0.04% to about 0.1% by weight, based upon the total weight of said composition; (c) cocaine HCl, wherein said cocaine HCl is contained in said composition in an amount of from about 3.0% to about 12.0% by weight, based upon the total weight of said composition; and (d) GELFOAM.RTM., wherein said Gelfoam.RTM. is contained in said composition in an amount of from about 6.0% to about 9.

Abstract: The invention presented relates to a stick delivery system for the topical application of a treatment agent. The inventive stick delivery system includes a solvent such as a polyhydric alcohol; a gelling agent which can be an alkali metal stearate, an alkali metal palmitate or mixtures thereof; and a treatment agent selected from the group consisting of an anesthetic, an antihistamine, an anti-inflammatory agent, an antifungal agent, or mixtures thereof.

Abstract: The present invention is directed to a method for anesthetizing teeth which does not require an injection into the gum in order to anesthetize a tooth (or teeth) which requires attention. The method comprises the step of applying a composition having a high concentration of potassium to a tooth requiring caries removal or manual manipulation thereof. The composition is adapted to anesthetize the tooth so that the tooth may be drilled or manually manipulated. It has been discovered that the potassium enters the dentinal tubules and odontoblastic fibrils and penetrates the pulpal tissues of the tooth for anesthetizing the tooth without having to inject anesthetics into the gum surrounding the tooth.

Abstract: A percutaneous anaesthetic delivery system comprises a skin conformable backing layer, an amethocaine-bearing material and a layer having little or no tendency to absorb amethocaine intermediate the backing layer and the layer of amethocaine bearing material which may be in the form of a film, mat or net.

Abstract: Liposome-encapsulated opioid analgesic agents delivered by the pulmonary route provide local, or systemic analgesia superior to that produced by the solution form of these agents administered by parentral (intravenous, intramuscular, or subcutaneous injection) or oral routes.

Abstract: A method of treating a pathological condition of an internal organ in a patient which comprises topically applying capsaicin to the skin of the patient containing nerves which lead to the spinal cord segments corresponding to the internal organ without the need of systemic absorption of the capsaicin.

Abstract: A drug delivery system for the topical administration of medication which utilizes a viscoelastic gel pad having a liquid fraction, wherein the medication is incorporated within the liquid fraction, the viscoelastic gel pad being partially encapsulated between two layers of liquid fraction impermeable material which are joined together to form a seal about the periphery of the gel pad so as to control migration of the pad, and the medicating skin contact of the pad is limited to a drug delivery aperture formed in the skin-contacting layer of liquid fraction impermeable material. The aperture-containing layer, which contacts a wearer's skin, may be provided with a pressure sensitive adhesive. The invention is exemplified in a topical anesthetic delivery system wherein a viscoelastic gel pad, partially encapsulated by transparent alcohol and water impermeable layers, has an alcohol and water liquid fraction in which is dissolved lidocaine base.

Abstract: A soybean lecithin based topical liniment and method of making the same is disclosed. The liniment utilizes soybean lecithin as a base and major ingredient and as the emulsifier which is mixed with plant oils, natural menthol, calcium stearate, and magnesium stearate. The soybean lecithin, plant oils, natural menthol, calcium stearate, and magnesium stearate are mixed together in predetermined relative proportions with the amount of soybean lecithin being greater than the sum of the amounts of the plant oils, natural menthol, calcium stearate, and magnesium stearate. The soybean lecithin, plant oils, natural menthol, calcium stearate, and magnesium stearate are added to one another and mixed together in a predetermined sequence to prevent precipitation and provide a homogenous mixture having a viscosity suitable for topical application.

Abstract: A method for treatment of ulcerative colitis (and sequelae to surgically treated colitis, for instance ileal pouchiris) and ulcerative proctitis comprising administration to a patient suffering therefrom of a therapeutically effective amount of a local anaesthetic or a pharmaceutically acceptable salt thereof, preferably lidocaine hydrochloride in the form of a pharmaceutically acceptable preparation.

Abstract: Novel pseudoceramides are defined, together with their synthesis and compositions comprising them for topical application to human skin, hair and nails.

Abstract: An anhydrous, topically-effective composition that resists phase separation and exhibits improved properties comprising a topically-active compound, such as an astringent salt; an improved suspending agent comprising a finely-divided silica and a suspending wax composition; and a suitable volatile liquid carrier, such as a volatile silicone or a volatile hydrocarbon. The suspending wax composition comprises a wax, an ester including at least 10 to about 32 carbon atoms and a volatile liquid carrier. The anhydrous, topically-effective composition is useful in topical cosmetic and medicinal preparations, such as antiperspirants, sunscreens and topical drug products, and is especially useful in cosmetic and medicinal preparations wherein an insoluble topically-active compound is dispersed throughout a liquid phase.

Abstract: Following completion of an operative procedure, the topical application of a cortisone preparation into the area of a postoperative wound is useful in ameliorating or eliminating postoperative pain. The postoperative wound can be treated with a local anesthetic agent prior to or during application of the cortisone preparation. The raw surgical surfaces of the wound are doused once with the cortisone preparation, for example, by direct spray with an atomizer or by irrigation with a syringe and needle. The cortisone is not irrigated out with saline following its application. Normal healing takes place.

Abstract: Products for cutaneous application with cosmetic and/or therapeutic effects, containing one or more active substances. This or these substances are carried by the microspheres of a polymer, dispersed in a liquid in which this polymer is not soluble.

Abstract: The present invention relates to a method of diagnosing and treating neuropathic pain syndromes with a composition of which Pelaroonium graveolens Ait. oil is the principle therapeutic agent. This oil is alternatively called geranium oil bourbon, oil geranium reunion, and oil rose-geranium. In particular, this invention discloses a method and composition to be used in treating and diagnosing neuropathic pain syndromes, including but not limited to Postherpetic Neuralgia and Reflex Syndrome Dystrophy, in which geranium oil bourbon is applied topically to the area affected with neuropathic pain symptoms.This invention provides a previously unavailable method for distinguishing pain caused by Postherpetic Neuralgia or by Reflex Syndrome Dystrophy from that caused by a host of other neuropathies. Additionally, this invention provides a previously unavailable means of treating the often unbearable pain caused by these two neuropathies.

Abstract: Liquefiable powder compositions are disclosed for the delivery of topical analgesics. In particular, microporous cellulosic powders, such as cellulose acetates or nitrates, are disclosed as high liquid content vehicles for the delivery of liquid analgesic preparations. The resulting powders permit the application of the analgesic preparation by simply rubbing or otherwise applying the formulation onto the skin in such a manner that the powder liquefies and appears to vanish. Upon application, the frangible liquid loaded cellulosic powders break up into minute particles that do not pass easily beyond the initial layers of the skin, but do permit the slow release of the analgesic agent for absorption into the skin.

Abstract: Clear, water-washable, non-greasy gels useful for topical pain relief contain capsaicin, water, alcohol and a carboxypoly-methylene emulsifier. A method of preparing the gels is disclosed.

Abstract: A transdermal therapeutic formulation comprising d-limonene and at least one pharmaceutically active substance wherein the content of the d-limonene is in the range from 0.1 to 2 weight percent, based on the total amount of the formulation. The transdermal therapeutic formulation has an excellent percutaneous absorption, is safe and is capable of delivering desired pharmaceutically active substances to a desired location of treatment or to the entire body of a patient through the circulatory system and is thus effective for curing various diseases.

Abstract: Novel antitussive and anesthetic liquid compositions of matter for oral use comprising an effective oral antitussive drug and dyclonine; and method of using same.

Abstract: A dispensing unit for a ketorolac topical gel formulation is disclosed, wherein the dispensing unit comprises a ketorolac topical gel formulation and a gas-impermeable multi-layered container wherein the container is comprised of a polyolefin inner layer and a metal foil outer layer.

Abstract: A long lasting, esthetically pleasing medicated skin care moisturizing composition comprising(1) an oil phase comprising oil from about 30% to about 80% and a non-ionic surface active agent having an HLB number of about 7 to about 12, wherein the non-ionic surface active agent is present in an amount of about 5% to about 9%;(2) an aqueous phase comprising an aqueous thickening agent from about 0.05% to about 5% and water from about 15% to about 65%;(3) an effective amount of a topical medicament; wherein the oil phase is added to the aqueous phase to form an emulsion and a topical medicament admixed into the emulsion has been developed.The method of preparation of the composition and a method of treating skin with the composition are also disclosed.

Abstract: A long lasting, esthetically pleasing medicated skin care moisturizing composition comprising(1) an oil phase comprising oil from about 30% to about 80% and a non-ionic surface active agent having an HLB number of about 7 to about 12, wherein the non-ionic surface active agent is present in an amount of about 5% to about 9%;(2) an aqueous phase comprising an aqueous thickening agent from about 0.05% to about 5% and water from about 15% to about 65%;(3) an effective amount of a topical medicament; wherein the medicament is a corticosteroid and the oil phase is added to the aqueous phase to form an emulsion and a topical medicament admixed into the emulsion has been developed.The method of preparation of the composition and a method of treating skin with the composition are also disclosed.

Abstract: A long lasting, esthetically pleasing skin care moisturizing composition comprising(1) an oil phase comprising oil from about 30% to about 80% and a non-ionic surface active agent having an HLB number of about 7 to about 12, wherein the non-ionic surface active agent is present in an amount of about 5% to about 9%;(2) an aqueous phase comprising an aqueous thickening agent from about 0.05% to about 5% and water from about 15% to about 65% wherein the oil phase is added to the aqueous phase to form an emulsion has been developed. The method of preparation of the composition and a method of treating skin with the composition are also disclosed.

Abstract: A long lasting, esthetically pleasing skin cleansing and care moisturizing composition comprising(1) an oil phase comprising oil from about 30% to about 80% and a non-ionic surface active agent having an HLB number of about 7 to about 12, wherein the non-ionic surface active agent is present in an amount of about 5% to about 9%;(2) an aqueous phase comprising an aqueous thickening agent from about 0.05% to about 5% and water from about 15% to about 65% wherein the oil phase is added to the aqueous phase to form an emulsion has been developed,(3) an effective amount of an abrasive to remove oily deposits, cosmetics and particulates from the skin surface.The method of preparation of the composition and a method of treating skin with the composition are also disclosed.

Abstract: Skin care cosmetic formulations which include a cellulosic polymer/solvent system capable of dispersing thin, substantive films on the skin are disclosed.

Abstract: Liposome encapsulated local anesthetic or analgesic agents when applied to skin or mucous membranes provided greater local anesthesia and analgesia than the same agents incorporated in conventional vehicles i.e., ointment, cream or lotion.

Abstract: An appetite suppressant oral composition containing Benzocaine, high impact flavor and a sweetening agent, in the form of a dental cream or a mouthspray. A novel method of reducing appetite and thereby intended for controlling weight of consumers, which comprises applying to the oral cavity a high impact flavor in a dentifrice or mouthspray.

Abstract: Disclosed are wax based cosmetic stick compositions comprising: from about 10% to about 50% of a wax type solidifying agent; and from about 5% to about 90% of a polyalphaolefin. These compositions preferably comprise from about 1.0% to about 40% of an active component, such as a sunscreen agent, analgesic, moisturizing and antiperspirant or a deodorant active.

Abstract: An appetite suppressant oral composition containing Benzocaine, high impact flavor and a sweetening agent, in the form of a dental cream or a mouthspray. A novel method of reducing appetite and thereby intended for controlling weight of consumers, which comprises applying to the oral cavity a high impact flavor in a dentrifrice or mouthspray.

Abstract: Disclosed is a pharmaceutical composition for use in desensitizing hypersensitive dentin or eliminating odontalgia comprising N-methacryloyl aminosalicylic acid as an active ingredient. The composition may further include an unsaturated compound and a polymerization initiator optionally for retaining the desensitizing effect.

Abstract: Pharmaceutical compositions in the form of a buccal tablet comprising etorphine or a salt thereof, at least one monosaccharide, disaccharide or a mixture thereof, and a mixture of xanthan gum and locust bean gum in a weight ratio 3:1 to 1:1, wherein the total weight of the mono- and/or di-saccharides relative to the combined weight of the xanthan and locust bean gums is in the ratio of 20:1 to 3:1. The tablet affords improved bioavailability.

Abstract: A composition and method of use for the treatment of pain and inflammation associated with lesions of the skin or mucus membrane, such as herpes simplex, herpes labialis, herpes progenitalis, chickenpox lesions, herpes genitalis, sensitivity of gingival tissue due to procedures for etching teeth with HCl, swollen gums, cheilosis, oral traumatic injuries, aphthous ulcer, by applying to the lesion an effective amount of a topical composition comprising diphenhydramine HCl, lidocaine HCl, aloe vera gel, propolis and sufficient base to raise the pH to 8-9.

Abstract: An analgesic stick composition comprising(i) a delivery system comprising about 10 to about 65% by weight alcohol; about 6 to about 10% by weight of an alkali metal salt of a saturated fatty acid gelling agent having from about C.sub.8 to about C.sub.22 ; about 10 to about 30% water; and(ii) an analgesic compound selected from the group consisting of oleoresin capsicum, capsicum, capsaicin, camphor, allyl isothiocyanate, methyl nicotinate, menthol and mixtures thereof.

Abstract: The local anesthetic, L-N-n-propylpipecolic acid-2,6-xylidide, namely: ##STR1## This compound is prepared by chlorinating L-pipecolic acid to yield the acid chloride, namely L-pipecolic acid chloride. The acid chloride is then reacted with 2,6-xylidine to yield L-pipecolic acid-2,6-xylidide. The L-N-pipecolic acid-2,6-xylidide is then propylated to yield the L-N-n-propylpipecolic acid-2,6-xylidide, which is a potent local anesthetic for humans and is of relatively low toxicity.

Abstract: An analgesia composition comprising an aqueous solution of a neurologically active agent in a concentration of from about 10.sup.-3 to about 10.sup.-13 grams/ml and a method of relieving pain comprising topically applying the composition to the genitalia of a human or non-human animal.

Abstract: Improved methods of anesthesia for mammals, especially humans, are provided wherein the prolonging effect upon local anesthesia which is exhibited by co-administration of vasoconstrictors, especially vasoconstrictors believed to act upon alpha adrenoreceptor sites on blood vessel walls, are provided. In accordance with a preferred embodiment, alpha adrenoreceptor blocking agents are aministered subsequent to the performance of surgery or dentistry under local anesthesia accomplished through co-administration of anesthesia and vasoconstrictor to cause reduction of prolonged anesthetic effect. Seriatim procedures are facilitated under local anesthesia through employment of the present invention. Improved patient aesthetics, diminution of self-inflicted trauma, and increased sensory feedback from patients are among the benefits conferred by the present invention.

Abstract: Local anesthesia is induced using microdroplets of a general anesthetic in liquid form. As an example, microdroplets of the general anesthetic methoxyfluorane coated by a unimolecular layer of dimysistoyl phosphatidylcholine are prepared by sonication. The microdroplets so prepared remain stable in physiologically-compatible solution, and are suitable for injection, typically intradermally or intraveneously, into a patient for inducing local anesthesia. These methoxyflurane-containing microdroplets have been demonstrated to cause long-term local anesthesia when injected intradermally, giving duration of anesthesia 28 times longer than with other anesthetics, such as lidocaine and 11 times longer than with bupivacaine.

Abstract: Novel liquid anesthetic aerosol composition comprising high concentrations of benzocaine in a water washable base with propellants which are resistant to cold temperatures are disclosed.

Abstract: The present invention relates to pharmacological active preparations, especially local anesthetic preparations and deals with the problem of i a obtaining a solution of a local anesthetic agent in the form of its base, where the concentration is higher than otherwise possible. This problem has been dissolved according to the present invention thereby that one local anesthetic agent in the form of its base and as such having a melting point of 30.degree. to 50.degree. C., preferably prilocaine or tetracaine, is provided with one other local anesthetic agent in the form of its base and as such having a melting point of above 30.degree. C., preferably above 40.degree. C., preferably bensocaine, lidocaine, bupivacaine, mepivacaine, etidocaine or tetracaine which agents when brought and heated together form a homogenous oil having a melting of preferably below 40.degree. C., more preferably below 25.degree. C.